Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: A randomized clinical trial

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 4, 2013, Pages 326-334

  Balaguer, J M ^a,b   Yu, C ^a   Byrne, J G ^a   Ball, S K ^a   Petracek, M R ^a   Brown, N J ^a   Pretorius, M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TN Valley Healthcare System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; AMINOCAPROIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ B2 RECEPTOR; CLOPIDOGREL; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICATIBANT; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MILRINONE; NORADRENALIN; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD LEVEL; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CRYOPRECIPITATE; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; ENZYME SYNTHESIS; ERYTHROCYTE TRANSFUSION; FEMALE; FIBRINOLYSIS; HEART SURGERY; HEART VALVE REPLACEMENT; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE TRANSFUSION;

6-AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENTS; BLOOD TRANSFUSION; BRADYKININ; CARDIOPULMONARY BYPASS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE HEMORRHAGE; RECEPTORS, BRADYKININ;

EID: 84875453100     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2012.249     Document Type: Article

References (46)

1. Bennett-Guerrero, E. et al. Variation in use of blood transfusion in coronary artery bypass graft surgery. JAMA 304, 1568-1575 (2010).
2. Khuri, S.F. et al. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J. Thorac. Cardiovasc. Surg. 104, 94-107 (1992).
3. Paramo, J.A., Rifon, J., Llorens, R., Casares, J., Paloma, M.J. & Rocha, E. Intra- and postoperative fibrinolysis in patients undergoing cardiopulmonary bypass surgery. Haemostasis 21, 58-64 (1991).
4. Levi, M. et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 354, 1940-1947 (1999).
5. Despotis, G.J., Avidan, M.S. & Hogue, C.W. Jr. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann. Thorac. Surg. 72, S1821-S1831 (2001).
6. Pretorius, M., McFarlane, J.A., Vaughan, D.E., Brown, N.J. & Murphey, L.J. Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass. Clin. Pharmacol. Ther. 76, 379-387 (2004).
7. Campbell, D.J., Dixon, B., Kladis, A., Kemme, M. & Santamaria, J.D. Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281, R1059-R1070 (2001).
8. Cugno, M., Nussberger, J., Biglioli, P., Alamanni, F., Coppola, R. & Agostoni, A. Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion. Chest 120, 1776-1782 (2001).
9. Vanhoutte, P.M. Endothelium and control of vascular function. State of the Art lecture. Hypertension 13, 658-667 (1989).
10. Brown, N.J., Gainer, J.V., Murphey, L.J. & Vaughan, D.E. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation 102, 2190-2196 (2000).
11. Pan, Z.K., Zuraw, B.L., Lung, C.C., Prossnitz, E.R., Browning, D.D. & Ye, R.D. Bradykinin stimulates NF-kappaB activation and interleukin 1beta gene expression in cultured human fibroblasts. J. Clin. Invest. 98, 2042-2049 (1996).
12. Brunius, G., Domeij, H., Gustavsson, A. & Yucel-Lindberg, T. Bradykinin upregulates IL-8 production in human gingival fibroblasts stimulated by interleukin-1beta and tumor necrosis factor alpha. Regul. Pept. 126, 183-188 (2005).
13. Santos, D.R., Calixto, J.B. & Souza, G.E. Effect of a kinin B2 receptor antagonist on LPS- and cytokine-induced neutrophil migration in rats. Br. J. Pharmacol. 139, 271-278 (2003).
14. Pretorius, M., Rosenbaum, D., Vaughan, D.E. & Brown, N.J. Angiotensinconverting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation 107, 579-585 (2003).
15. Souza, D.G. et al. Role of bradykinin B2 and B1 receptors in the local, remote, and systemic inflammatory responses that follow intestinal ischemia and reperfusion injury. J. Immunol. 172, 2542-2548 (2004).
16. Souza, D.G. et al. Role of the bradykinin B2 receptor for the local and systemic inflammatory response that follows severe reperfusion injury. Br. J. Pharmacol. 139, 129-139 (2003).
17. Fein, A.M. et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA 277, 482-487 (1997).
18. Witherow, F.N., Dawson, P., Ludlam, C.A., Webb, D.J., Fox, K.A. & Newby, D.E. Bradykinin receptor antagonism and endothelial tissue plasminogen activator release in humans. Arterioscler. Thromb. Vasc. Biol. 23, 1667-1670 (2003).
19. Pretorius, M., Murphey, L.J., McFarlane, J.A., Vaughan, D.E. & Brown, N.J. Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass. Circulation 108, 3079-3083 (2003).
20. Maurer, M. et al. New topics in bradykinin research. Allergy 66, 1397-1406 (2011).
21. Witherow, F.N., Dawson, P., Ludlam, C.A., Fox, K.A. & Newby, D.E. Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy. J. Am. Coll. Cardiol. 40, 961-966 (2002).
22. Oliver, J.J., Webb, D.J. & Newby, D.E. Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. Arterioscler. Thromb. Vasc. Biol. 25, 2470-2479 (2005).
23. Vaughan, D.E. PAI-1 and atherothrombosis. J. Thromb. Haemost. 3, 1879-1883 (2005).
24. Shariat-Madar, Z. et al. Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood 108, 192-199 (2006).
25. Marney, A.M., Ma, J., Luther, J.M., Ikizler, T.A. & Brown, N.J. Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis. J. Am. Soc. Nephrol. 20, 2246-2252 (2009).
26. Barratt-Due, A. et al. The role of bradykinin and the effect of the bradykinin receptor antagonist icatibant in porcine sepsis. Shock 36, 517-523 (2011).
27. Ray, M.J., Hales, M. & Marsh, N. Epsilon-aminocaproic acid promotes the release of alpha2-antiplasmin during and after cardiopulmonary bypass. Blood Coagul. Fibrinolysis 12, 129-135 (2001).
28. Greilich, P.E., Brouse, C.F., Whitten, C.W., Chi, L., Dimaio, J.M. & Jessen, M.E. Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebocontrolled study of epsilon-aminocaproic acid and aprotinin. J. Thorac. Cardiovasc. Surg. 126, 1498-1503 (2003).
29. Greilich, P.E. et al. Effects of epsilon-aminocaproic acid and aprotinin on leukocyte-platelet adhesion in patients undergoing cardiac surgery. Anesthesiology 100, 225-233 (2004).
30. Eisses, M.J., Seidel, K., Aldea, G.S. & Chandler, W.L. Reducing hemostatic activation during cardiopulmonary bypass: a combined approach. Anesth. Analg. 98, 1208-1216, table of contents (2004).
31. Hardy, J.F. et al. Prophylactic tranexamic acid and epsilon-aminocaproic acid for primary myocardial revascularization. Ann. Thorac. Surg. 65, 371-376 (1998).
32. Kluger, R., Olive, D.J., Stewart, A.B. & Blyth, C.M. Epsilon-aminocaproic acid in coronary artery bypass graft surgery: preincision or postheparin? Anesthesiology 99, 1263-1269 (2003).
33. Troianos, C.A. et al. The effect of prophylactic epsilon-aminocaproic acid on bleeding, transfusions, platelet function, and fibrinolysis during coronary artery bypass grafting. Anesthesiology 91, 430-435 (1999).
34. Kikura, M., Levy, J.H., Tanaka, K.A. & Ramsay, J.G. A double-blind, placebocontrolled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery. J. Am. Coll. Surg. 202, 216-222; quiz A44 (2006).
35. Brown, J.R., Birkmeyer, N.J. & O'Connor, G.T. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 115, 2801-2813 (2007).
36. Bennett-Guerrero, E. et al. Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations: a randomized, blinded clinical trial. Anesthesiology 87, 1373-1380 (1997).
37. Greilich, P.E. et al. The effect of epsilon-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: a randomized, double-blind, placebo-controlled, noninferiority trial. Anesth. Analg. 109, 15-24 (2009).
38. Fergusson, D.A. et al. A comparison of aprotinin and lysine analogues in highrisk cardiac surgery. N. Engl. J. Med. 358, 2319-2331 (2008).
39. Butterworth, J., James, R.L., Lin, Y., Prielipp, R.C. & Hudspeth, A.S. Pharmacokinetics of epsilon-aminocaproic acid in patients undergoing aortocoronary bypass surgery. Anesthesiology 90, 1624-1635 (1999).
40. Greilich, P.E., Okada, K., Latham, P., Kumar, R.R. & Jessen, M.E. Aprotinin but not epsilon-aminocaproic acid decreases interleukin-10 after cardiac surgery with extracorporeal circulation: randomized, double-blind, placebo-controlled study in patients receiving aprotinin and ε-aminocaproic acid. Circulation 104, I265-I269 (2001).
41. Kawahito, K., Adachi, H. & Ino, T. Influence of surgical procedures on interleukin-6 and monocyte chemotactic and activating factor responses: CABG vs. valvular surgery. J. Interferon Cytokine Res. 20, 1-6 (2000).
42. Whitten, C.W., Hill, G.E., Ivy, R., Greilich, P.E. & Lipton, J.M. Does the duration of cardiopulmonary bypass or aortic cross-clamp, in the absence of blood and/or blood product administration, influence the IL-6 response to cardiac surgery? Anesth. Analg. 86, 28-33 (1998).
43. Mehta, R.L. et al.; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care 11, R31 (2007).
44. Macedo, E., Malhotra, R., Claure-Del Granado, R., Fedullo, P. & Mehta, R.L. Defining urine output criterion for acute kidney injury in critically ill patients. Nephrol. Dial. Transplant. 26, 509-515 (2011).
45. Vaughan, D.E., Rouleau, J.L., Ridker, P.M., Arnold, J.M., Menapace, F.J. & Pfeffer, M.A. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 96, 442-447 (1997).
46. Pretorius, M., Rosenbaum, D.A., Lefebvre, J., Vaughan, D.E. & Brown, N.J. Smoking impairs bradykinin-stimulated t-PA release. Hypertension 39, 767-771 (2002).